Midstream’s Series A round was led by Valtruis, and included participation from Andreessen Horowitz (a16z), Foundry and CommonSpirit Ventures. The post Midstream Health Snags $20M to Provide Health Systems More Financial Stability appeared first on MedCity News.

Setara Biosciences’ lead program is a potential treatment for the rare neuromuscular disorder Charcot-Marie-Tooth disease type 2C and the prevalent condition overactive bladder. This small molecule came from Actio Biosciences, which was recently acquired by Jazz Pharmaceuticals. The post Rare Disease Biotech Setara Starts Out With $90M and a Lead Drug in the Clinic appeared first on MedCity News.

Medical Microinstruments (MMI) has raised $125 million in Series D financing to expand the reach of its Symani Surgical System and investigate new applications for microsurgery, including an experimental approach to treat Alzheimer’s disease. The post MMI Raises $125M to Expand Robotic Microsurgery and Explore New Treatments appeared first on MedCity News.

One question on everyone’s mind is what the impact of the midterm elections will be on the US healthcare system in the near and long term – here are 3 possible outcomes The post What the Midterms Mean for Healthcare and the Investors Betting on It appeared first on MedCity News.

An employer that treats board disclosure, community benefit reporting, and contracting terms as three separate conversations is missing that they are the same conversation. The post Prestige Is a Business Model appeared first on MedCity News.

The Department of Labor finalized a rule that seeks to bring more transparency into PBM compensation. The post Employer, Pharmacy Advocates Applaud DOL Final Rule on PBMs appeared first on MedCity News.

Bambusa Therapeutics’ IPO cash will support its pipeline of bispecific antibodies designed to offer advantages over currently available monoclonal antibodies. Aspen Neuroscience also debuted on the Nasdaq as it prepares for a pivotal test of its Parkinson’s disease cell therapy. The post Bambusa IPO Brings In $169M to Break Immunology’s ‘Therapeutic Ceiling’ appeared first on MedCity News.

For life science employers who offer these benefits should pay particular attention to new state laws and regulations to ensure continued compliance. The post It’s A TRAP! Employer Concerns for Tuition Reimbursement and Other Employee Repayment Agreements appeared first on MedCity News.

CMS asked the right questions – the ones that will determine whether any future benefit actually reaches these patients. The post A Meaningful Signal on Palliative Care – But Not Yet a Benefit appeared first on MedCity News.

At MedCity INVEST Digital Health, experts from Jona, Labcorp and Evvy discussed the drivers of consumer diagnostics. The post What’s Driving the Rise of Consumer Diagnostics? appeared first on MedCity News.

BioMarin gains rights to a Fabry disease enzyme replacement therapy with potential dosing advantages over products from Sanofi and Chiesi Group. BioMarin’s new clinical-stage asset could reach patients ineligible for the Fabry drug that came with its Amicus Therapeutics acquisition earlier this year. The post BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting Fabry Drug appeared first on MedCity News.

Scientific progress only really matters if it changes what life looks like for those living with OCD. That’s because for someone who has spent years losing hours to their obsessions and compulsions, meaningful progress should mean a significant change in their lives. The post Beyond a Score: Putting The Patient Experience at the Heart of OCD Innovation appeared first on MedCity News.

[Sponsored] Pregnancy and NICU admissions are among the most complex areas in healthcare. A new report from ProgenyHealth highlights how the company can work with Medicaid and commercial health plans to uncover insights and hidden risks critical to improving maternal and infant care and reducing costs. The post 3 Ways ProgenyHealth Can Transform Maternity and Infant Health, Claims Management appeared first on MedCity News.

Democratic senators are investigating 10 insurers’ role in the Trump administration’s termination of 760,000 ACA enrollees’ coverage over suspected fraud. The post Senators Investigate Insurers’ Role in Removing Thousands from ACA Coverage appeared first on MedCity News.

Topline Phase 3 results show Eli Lilly’s retatrutide beat Novo’s Ozempic on measures of blood sugar and weight loss in adults with type 2 diabetes. Retatrutide is a peptide designed to activate three metabolic targets versus just one hit by Ozempic. The post Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial appeared first on MedCity News.